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Background
The beta-secretase enzyme BACE1 initiates the produc-
tion of beta-amyloid (Abeta), the presumptive cause of
Alzheimer’s disease (AD). Recent promising advances have
been made toward the identification of BACE1 inhibitor
drugs. However, the development of BACE1 drugs has
also proven challenging. Other targets upstream of BACE1
responsible for the regulation of enzyme levels and activity
should be identified and evaluated, as they may offer alter-
native or complementary therapeutic strategies to direct
BACE1 inhibition. Of particular relevance in this regard is
the observation that BACE1 levels are elevated in AD
brain, suggesting increased BACE1 levels may play a role
in AD pathogenesis. If so, normalizing BACE1 levels may
prove therapeutically efficacious while still allowing nor-
mal BACE1 function. Interestingly, impaired glucose
metabolism occurs early in AD, and our work has demon-
strated that glucose deprivation increases BACE1 levels
and Abeta production in the brains of an APP transgenic
model of AD, the Tg2576 mouse. We have identified the
molecular mechanism of the BACE1 increase and showed
that glucose deprivation induces phosphorylation of the
translation initiation factor eIF2alpha (eIF2a-P), which in
turn increases the translation of BACE1.
Methods
BACE1-overexpressing 293 cells, primary neuron cultures,
APP transgenic mice, and AD brain samples were ana-
lyzed by western blot for BACE1, eIF2alpha, and other
markers. Genetic and pharmacological manipulation of
eIF2alpha phosphorylation was performed in vitro experi-
ments. eIF2alpha S51A knock-in mice and GADD34-AAV
injection into mouse brain was used for manipulation of
eIF2alpha phosphorylation in vivo.
Results
Pharmacologically inducing eIF2alpha phosphorylation
directly increases BACE1 levels. Conversely, genetically
preventing eIF2alpha phosphorylation blocks the glucose
deprivation-induced BACE1 increase. Chronic glucose
deprivation in Tg2576 mice increases levels of eIF2a-P,
BACE1, Abeta, and amyloid plaques. Importantly, eIF2a-P
and BACE1 are elevated in aggressive plaque-forming
5XFAD transgenic mice, and levels of BACE1, eIF2a-P,
and amyloid are all correlated in humans with AD. Abeta
itself also appears to increase eIF2a-P and BACE1 in vivo.
Conclusion
These results strongly suggest that eIF2alpha phosphory-
lation increases BACE1 levels and causes Abeta overpro-
duction, which could be an early, initiating molecular
mechanism in sporadic AD. Taken together, our work is
consistent with the hypothesis that impaired glucose
metabolism may lead to increased BACE1 levels by the
eIF2a-P translational mechanism, and subsequent eleva-
tion of Abeta generation. Once amyloid plaques form,
Abeta causes BACE1 levels to increase further, thus
accelerating Abeta generation and plaque growth via a
positive-feedback loop.
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